-
IntelGenx Q2 2023: Revenue Decline 67%, Operating Costs Rise, What About Net Loss?
Monday, August 14, 2023 - 10:54pm | 543Read More...IntelGenx Technologies Corp. (TSX: IGX) (OTC: IGXT), a drug delivery company focused on the development and manufacturing of pharmaceutical films, reported its financial results on Monday for the second quarter ending on June 30, 2023. IntelGenx: 67% Revenue Dip, Strategic Successes - Can It...
-
FDA Gives Nod To IntelGenx's Migraine Solution As Revenues Plunge 32%; Q1 Results Report
Thursday, May 11, 2023 - 6:33pm | 341Read More...IntelGenx Technologies Corp. (OTC: IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same period last year. The company's net comprehensive loss was $2.9 million, slightly lower than...
-
IntelGenx Reports Q3 2022 Financial Results, Management Anticipates Psychedelics Trials In 2023
Thursday, November 10, 2022 - 7:21pm | 424Read More...IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) reported its financial results late Thursday for the third quarter that ended September 30, 2022. Dr. Horst G. Zerbe, CEO of IntelGenx called the third quarter a “productive one” for IntelGenx, marked by the achievement of...
